Role of Biomarkers in Prediction of Cardiotoxicity During Cancer Treatment

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Purpose of review

As cancer survivor rates improve with early screening and modern treatment options, cardiotoxicity is becoming an increasing problem. It is imperative for physicians to recognize adverse events early so that appropriate measures can be taken before advanced and permanent cardiac dysfunction ensues. In this review, we will evaluate the literature surrounding current cardiac biomarkers in the detection of cardiotoxicity during cancer treatment as well as discuss the role of emerging novel biomarkers.

Recent findings

Troponin and brain natriuretic peptides show promise in the detection of subclinical cardiotoxicity during cancer treatment. In addition to identifying late complications among cancer survivors, they have the potential to predict patients who are at risk of developing cardiotoxicity prior to the initiation of cancer therapy. However, there are also conflicting data due to varying study design.

Summary

Although biomarkers are an attractive option in the detection of cardiotoxicity among cancer patients, current recommendations surrounding its role are based on expert consensus opinion. Further research with appropriately designed prospective trials is required to guide optimal clinical practice.

Related collections

Most cited references 53

Record: found
Abstract: found
Article: not found

Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.

Susan Dent, Saro Armenian, Ana Barac … (2017)

Purpose Cardiac dysfunction is a serious adverse effect of certain cancer-directed therapies that can interfere with the efficacy of treatment, decrease quality of life, or impact the actual survival of the patient with cancer. The purpose of this effort was to develop recommendations for prevention and monitoring of cardiac dysfunction in survivors of adult-onset cancers. Methods Recommendations were developed by an expert panel with multidisciplinary representation using a systematic review (1996 to 2016) of meta-analyses, randomized clinical trials, observational studies, and clinical experience. Study quality was assessed using established methods, per study design. The guideline recommendations were crafted in part using the Guidelines Into Decision Support methodology. Results A total of 104 studies met eligibility criteria and compose the evidentiary basis for the recommendations. The strength of the recommendations in these guidelines is based on the quality, amount, and consistency of the evidence and the balance between benefits and harms. Recommendations It is important for health care providers to initiate the discussion regarding the potential for cardiac dysfunction in individuals in whom the risk is sufficiently high before beginning therapy. Certain higher risk populations of survivors of cancer may benefit from prevention and screening strategies implemented during cancer-directed therapies. Clinical suspicion for cardiac disease should be high and threshold for cardiac evaluation should be low in any survivor who has received potentially cardiotoxic therapy. For certain higher risk survivors of cancer, routine surveillance with cardiac imaging may be warranted after completion of cancer-directed therapy, so that appropriate interventions can be initiated to halt or even reverse the progression of cardiac dysfunction.

0 comments Cited 429 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: found

Doxorubicin Cardiomyopathy

Kanu Chatterjee, Jianqing Zhang, Norman Honbo … (2010)

Established doxorubicin cardiomyopathy is a lethal disease. When congestive heart failure develops, mortality is approximately 50%. Extensive research has been done to understand the mechanism and pathophysiology of doxorubicin cardiomyopathy, and considerable knowledge and experience has been gained. Unfortunately, no effective treatment for established doxorubicin cardiomyopathy is presently available. Extensive research has been done and is being done to discover preventive treatments. However an effective and clinically applicable preventive treatment is yet to be discovered.

0 comments Cited 321 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines.

G Curigliano, D Cardinale, T Suter … (2012)

Cardiovascular (CV) toxicity is a potential short- or long-term complication of various anticancer therapies. Some drugs, such as anthracyclines or other biological agents, have been implicated in causing potentially irreversible clinically important cardiac dysfunction. Although targeted therapies are considered less toxic and better tolerated by patients compared with classic chemotherapy agents, rare but serious complications have been described, and longer follow-up is needed to determine the exact profile and outcomes of related cardiac side-effects. Some of these side-effects are irreversible, leading to progressive CV disease, and some others induce reversible dysfunction with no long-term cardiac damage to the patient. Assessment of the prevalence, type and severity of cardiac toxicity caused by various cancer treatments is a breakthrough topic for patient management. Guidelines for preventing, monitoring and treating cardiac side-effects are a major medical need. Efforts are needed to promote strategies for cardiac risk prevention, detection and management, avoiding unintended consequences that can impede development, regulatory approval and patient access to novel therapy. These new ESMO Clinical Practice Guidelines are the result of a multidisciplinary cardio-oncology review of current evidence with the ultimate goal of providing strict criteria-based recommendations on CV risk prevention, assessment, monitoring and management during anticancer treatment.

0 comments Cited 232 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Alexander R. Lyon: +44 (0) 207 352 8121 , a.lyon@ic.ac.uk

Journal

Journal ID (nlm-ta): Curr Treat Options Cardiovasc Med

Journal ID (iso-abbrev): Curr Treat Options Cardiovasc Med

Title: Current Treatment Options in Cardiovascular Medicine

Publisher: Springer US (New York )

ISSN (Print): 1092-8464

ISSN (Electronic): 1534-3189

Publication date (Electronic): 19 June 2018

Publication date PMC-release: 19 June 2018

Publication date (Print): 2018

Volume: 20

Issue: 7

Electronic Location Identifier: 55

Affiliations

[1 ]GRID grid.439338.6, Cardio-Oncology Service, Department of Cardiology, , Royal Brompton Hospital, ; London, SW3 6NP UK

[2 ]ISNI 0000 0004 0621 9599, GRID grid.412106.0, Department of Cardiology, , National University Heart Centre Singapore, ; Singapore, Singapore

[3 ]ISNI 0000 0001 2113 8111, GRID grid.7445.2, National Heart and Lung Institute, , Imperial College London, ; London, UK

Article

Publisher ID: 641

DOI: 10.1007/s11936-018-0641-z

PMC ID: 6008350

PubMed ID: 29923056

SO-VID: c6d490f7-eae9-486b-bd55-c2cae94fac27

License:

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

History

Funding

Funded by: Imperial College London

Custom metadata

ScienceOpen disciplines: Cardiovascular Medicine

Keywords: biomarkers,troponin,brain natriuretic peptide,chemotherapy,cardiotoxicity

Data availability:

ScienceOpen disciplines: Cardiovascular Medicine

Keywords: biomarkers, troponin, brain natriuretic peptide, chemotherapy, cardiotoxicity

Role of Biomarkers in Prediction of Cardiotoxicity During Cancer Treatment

Read this article at

Abstract

Purpose of review

Recent findings

Summary

Related collections

Journal of Circulating Biomarkers

Most cited references 53

Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.

Doxorubicin Cardiomyopathy

Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines.

Author and article information

Contributors

Journal

Affiliations

Article

History

Funding

Categories

Custom metadata

Comments

Comment on this article

Similar content 363

Cited by 32

Most referenced authors 1,872